Auris Medical Holding AG (NASDAQ:EARS) was the recipient of a significant drop in short interest in October. As of October 31st, there was short interest totalling 1,176,457 shares, a drop of 60.0% from the October 15th total of 2,942,457 shares. Approximately 6.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 11,134,463 shares, the short-interest ratio is presently 0.1 days.

A number of analysts recently weighed in on EARS shares. ValuEngine upgraded shares of Auris Medical from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. Eurobank EFG started coverage on shares of Auris Medical in a report on Monday, October 8th. They set a “buy” rating and a $2.50 target price for the company.

Shares of NASDAQ:EARS opened at $0.68 on Friday. The company has a market cap of $4.32 million, a P/E ratio of -0.12 and a beta of -1.09. Auris Medical has a 1-year low of $0.23 and a 1-year high of $9.50.

Auris Medical (NASDAQ:EARS) last issued its earnings results on Wednesday, August 15th. The biotechnology company reported ($0.51) earnings per share for the quarter. On average, equities research analysts predict that Auris Medical will post -0.48 EPS for the current fiscal year.

An institutional investor recently bought a new position in Auris Medical stock. Bellevue Group AG acquired a new position in Auris Medical Holding AG (NASDAQ:EARS) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 193,125 shares of the biotechnology company’s stock, valued at approximately $151,000. Bellevue Group AG owned 3.16% of Auris Medical as of its most recent filing with the SEC. 17.96% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Auris Medical Holding AG (EARS) Short Interest Down 60.0% in October” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at

Auris Medical Company Profile

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.

See Also: Intrinsic Value

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with's FREE daily email newsletter.